BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 6, 2026
Home » Authors » Nuala Moran

Articles by Nuala Moran

Biogen Idec Forms Parkinson's Deal With Vernalis For $100M

June 25, 2004
By Nuala Moran

Biogen Idec Forms Parkinson's Deal With Vernalis For $100M

June 25, 2004
By Nuala Moran

Planning Phase III, Onyvax Mulling Financing Options

June 23, 2004
By Nuala Moran

Planning Phase III, Onyvax Mulling Financing Options

June 23, 2004
By Nuala Moran

FBI: Biotech Industry Not Facing Serious Problem' Of Extremists

June 21, 2004
By Nuala Moran

Strakan, ProSkelia Merging, Building 'Company To Last'

June 16, 2004
By Nuala Moran

Vectura, Evolutec File To Try IPO Luck On London Market

June 16, 2004
By Nuala Moran
LONDON - There are further signs that the UK's initial public offering drought might be nearing an end, as Vectura Ltd. and Evolutec Group plc announced plans to float on London's Alternative Investment Market, looking for £20 million to £25 million (US$32.3 million to US$45.3 million) and £7.5 million, respectively. (BioWorld International)
Read More

Vectura, Evolutec File To Try IPO Luck On London Market

June 16, 2004
By Nuala Moran
LONDON - There are further signs that the UK's initial public offering drought might be nearing an end, as Vectura Ltd. and Evolutec Group plc announced plans to float on London's Alternative Investment Market, looking for £20 million to £25 million (US$32.3 million to US$45.3 million) and £7.5 million, respectively. (BioWorld International)
Read More

Strakan, ProSkelia Merging, Building 'Company To Last'

June 16, 2004
By Nuala Moran

Cancer Researchers Continue Radioimmunotherapy Exploration

June 11, 2004
By Nuala Moran
Previous 1 2 … 444 445 446 447 448 449 450 451 452 … 532 533 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 5, 2026.
  • Brain and virus with chromosome

    CROI 2026: Neurodegeneration, the challenge of aging with HIV

    BioWorld
    Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
  • Depression concept with human, broken brain and heavy rain

    CROI 2026 highlights depression and cognitive vulnerability in HIV

    BioWorld
    The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 3, 2026
  • Concept art for headache

    Slate Medicines launches with focus on headache disorders

    BioWorld Science
    Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing